Table 2.
Characteristics of the studies included in Section 2.
| Author, Year | Flavonoid | Angiogenesis Promoter | Cell Line | Concentration | Time, Duration of Treatment | Results Representation | n |
|---|---|---|---|---|---|---|---|
| Soo Jin Oh, 2010 [95] | Quercetin | NA | TAMR-MCF-7 | 3, 10, 30 µM | NA | Number of branches | 5 to 7 |
| Chiu-Mei Lin, 2006 [130] | Wogonin | LPS (1µg/mL) | NA | 10−5, 10−6, 10−7, 10−8 M | 10th day, 48 h | Percentage of vascular counts (%) | 3 |
| Ling-Zhi Liu, 2011 [131] | Acacetin | NA | OVCAR-3 | 10 µM | 9th day, 4 days | Relative angiogenesis | 5 |
| Kai Zhao, 2018 [132] | Wogonin, LW-215 | NA | NA | Wogonin: 80 ng/CAM, LW-215: 2, 4, 8 ng/CAM | 10th day, 48 h | The number of new vessels (% of control) | 3 |
| Haizhi Huang, 2015 [42] | Galangin, myricetin | NA | OVCAR-3 | G: 40 µM, M: 20 µM | 9th day, 5 days | Blood vessels (%) | 6 |
| Olga Viegas, 2019 [133] | Cyanidin, C-3-O-glucoside, delphinidin, D-3-O-glucoside | NA | NA | 20, 40, 80, 100, 200 µM | 11th day, 48 h | % of control | 5 |
| Wen-fu Tan, 2003 [100] | Quercetin | NA | NA | 25, 50, 100 nmol/10 µL/CAM | 10th day, 48 h | Microscopic pictures | 10 |
| Rajesh Gacche, 2010 [134] | Flavone, 3/5/6/7/-Hydroxy flavone | NA | NA | 10, 50, 100 µM | 10th day, 48 h | Antiangiogenic activity (%) of selected flavonoids | 8 |
| R.N. Gacche, 2011 [135] | 3, 6-DHF, 3, 7-DHF, 5, 7-DHF, apigenin, genistein, kaempferol, luteolin, fisetin, rutin, quercetin | NA | NA | 10, 50, 100 µM in 0.05% DMSO/20 µL/CAM | 10th day, 48 h | Antiangiogenic activity (%) of selected flavonoids | 8 |
| R.N. Gacche, 2015 [136] | 4′-Methoxy flavone, 3-Hydroxy-7-methoxy flavone, Formononetin, Biochanin-A, Diosmin, Hesperitin, Hesperidin, 2′-Hydroxy flavanone, 4′-Hydroxy flavanone, 7-Hydroxy flavanone, Myricetin, Taxifolin, Silibinin, Silymarin, Naringenin, Naringin, Catechin | NA | NA | 10, 50, 100 µM in 0.05% DMSO/20 µL/CAM | 10th day, 48 h | Antiangiogenic activity (%) of selected flavonoids | 8 |
| Yan Chen, 2010 [137] | LYG-202 | NA | NA | 2.4, 12, 60 ng/CAM | 10th day, 48 h | Percentage of vascular counts (% of control) | 10 |
| Hisanori Hattori, 2011 [18] | Beturetol, isosakuranetin | NA | NA | 300 ng/CAM | 5th day, 7 days | Inhibition % of angiogenesis at 300 ng/CAM. | 10 |
| Yujie Huang, 2019 [138] | Wogonoside | NA | MDA-MB-231, MDA-MB-468 | 50, 100, 200 ng/CAM | 10th day, 48 h | Number of new vessels (% cells) | 3 |
| Yan Chen, 2009 [139] | Wogonoside | LPS (1µg/mL) | NA | 1.5, 15, 150 ng/CAM | 10th day, 48 h | Number of vessels (% of LPS) | 10 |
| Xiaobo Li, 2017 [140] | Luteolin | Gas6 (300 ng/mL) | NA | 10, 20 µM | 6th day, 48 h | Relative vascular density (% of control) | 3 |
| Siva Prasad Panda, 2019 [141] | TMF | NA | EAT | 10, 17, 25 µg/mL | 5th day, 11 days | Microscopic pictures | 5 |
| Yujie Huang, 2016 [142] | Wogonoside | NA | MCF-7 | 50, 100, 200 ng/CAM | 10th day, 48 h | Number of new vessels (% MCF-7) | 3 |
| Tariq A. Bhat, 2013 [143] | Acacetin | NA | NA | 50 µM | 6th day, (every 48 h for 8 days) | % capillary formation | 5 independent areas on CAMs for each treatment |
| Jing Fang, 2007 [144] | Apigenin | NA | OVCAR-3, PC-3 | OVCAR-3: 7.5, 15 µM, PC-3: 10, 20 µM |
9th day, 4 days | Quantification of blood vessels on the CAM | 8 |
| Jianchu Chen, 2015 [145] | Nobiletin | NA | A2780 | 20 µM | 9th day, 5 days | Blood vessel count | 10 |
| Poyil Pratheeshkumar, 2012 [146] | Luteolin | NA | NA | 20, 40 µM | 8th day, 48 h | Relative vascular density | 3 |
| Chiu-Mei Lin, 2006 [147] | Wogonin | IL-6 (10 ng/mL) | NA | 10−5, 10−6, 10−7, 10−8 M | 10th day, 48 h | Percentage of vascular count (%) | 3 |
| Dongqing Zhu, 2016 [148] | Baicalin, baicalein | NA | NA | 0.5, 2, 10, 50 µg/mL and 0.2, 1, 5 mg/mL | 7.5th day, 48 h | Number of new blood vessels | 30 |
| Haitao Luo, 2009 [70] | Kaempferol | NA | OVCAR-3 | 20 µM | 9th day, 5 days | Blood vessel count | 5 |
| Laure Favot, 2003 [149] | Delphinidin | NA | NA | 2, 10, 25, 50 µg | 8th day, 48 h | Microscopic pictures | 5 |
n = number of CAMs used in each experiment; NA, Not available; DHF, Dihydroxyflavone; TMF, Trimethoxyflavonoid; TMAR, Tamoxifen breast cancer resistant cell line; MCF-7, Breast cancer cell line; LPS, Lipopolysaccharide; OVCAR-3, Ovarian cancer cell line; MDA-MB-231, MDA-MB-468, Triple negative breast cancer cell lines; Gas6, Growth arrest specific 6; EAT, Mouse breast carcinoma (Ehrlich-Lettre Ascites); PC-3, Prostate cancer cell line; A2780, ovarian cancer cell line; IL-6, Interleukin 6.